Independent GLP-1 education for people who want to understand their options without being sold to.
SlimInsider is an independent educational resource covering GLP-1 weight loss medications, semaglutide, tirzepatide, and what's coming next. We publish plainly written guides on how these medications work, what they cost, how to access them legally, what to expect from treatment, and how to evaluate the providers offering them online.
We are not a medical provider. We don't prescribe, diagnose, or give medical advice. Everything we publish is for education, to help people ask better questions of their doctors and make more informed decisions about their own health care.
Most information about GLP-1 medications online comes from the clinics and providers who profit from prescribing them, or from pharmaceutical companies with their own marketing interests. The result is a landscape where accurate, independent information is hard to find.
We exist to fill that gap. Our editorial content isn't influenced by affiliate relationships, provider partnerships, or advertising. We cover the topics people actually need: real costs, real side effects, how to tell legitimate providers from predatory ones, and what the clinical evidence actually shows, including the uncomfortable parts.
SlimInsider earns revenue through affiliate marketing. When a reader uses an affiliate link to sign up with a recommended provider, we earn a commission at no additional cost to the reader.
We disclose affiliate relationships clearly, in every article footer, in email communications, and on our Affiliate Disclosure page. Affiliate relationships don't influence which topics we cover or what we say about them. We only recommend providers that meet our vetting criteria.
We only recommend providers that meet all of the following criteria:
We do not accept payment from providers for positive coverage. If a provider we recommend no longer meets these criteria, we remove or update our recommendation.
We cite primary sources, clinical trials, FDA documents, peer-reviewed research, wherever possible. We distinguish between what the evidence shows and what is still uncertain. We update articles when new data changes our assessment.
The GLP-1 regulatory and clinical landscape changes frequently. We date our content and note when updates are needed.
Questions, corrections, topic suggestions, or partnership inquiries: contact us here.